Innovative Medical Technology Advances with First Patient Enrollments

Industry Overview - The Medical Technology market is projected to reach US$597.00 billion by 2024, with Medical Devices expected to dominate at US$508.00 billion. The market is anticipated to grow at a steady annual rate of 5.29% from 2024 to 2029 [2][20]. Company Highlights: Aethlon Medical, Inc. - Aethlon Medical has enrolled the first patient in its clinical trial for the Hemopurifier®, aimed at treating solid tumors during anti-PD-1 therapy. This milestone was achieved on October 29, 2024, at the Royal Adelaide Hospital in Australia [3][6]. - The Hemopurifier is designed to remove life-threatening viruses and harmful exosomes from biological fluids, potentially improving therapeutic responses to anti-PD-1 therapies like Keytruda® and Opdivo® [4][6]. - Current response rates to anti-PD-1 therapies are approximately 30-40%, and the Hemopurifier aims to enhance these rates by targeting extracellular vesicles (EVs) implicated in cancer spread and therapy resistance [6][7]. Clinical Trial Details - The trial will involve approximately 9 to 18 patients, focusing on safety, feasibility, and dose-finding, with the primary endpoint being the incidence of adverse events and significant changes in safety lab tests [7][8]. - Patients will undergo a two-month run-in period with anti-PD-1 therapy, after which those not responding will receive Hemopurifier treatments [5][7]. Other Notable Developments in Medical Technology - Royal Philips has initiated the THOR IDE clinical trial, studying a combined laser atherectomy and intravascular lithotripsy catheter, which simplifies procedures for treating peripheral artery disease (PAD) [9][12]. - Microbot Medical has completed enrollment for its ACCESS-PVI clinical trial and plans to file for FDA clearance by the end of 2024 [13][14]. - BD (Becton, Dickinson and Company) has also enrolled the first patient in its AGILITY study, assessing a self-expanding vascular covered stent for PAD treatment [17][19].